Kyang Lee S, Howard Andrew, Alzahrani Nayef A, Morris David L
Department of Surgery, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia.
Department of Anaesthesia, St George Hospital, Sydney, New South Wales, Australia.
Int J Surg Case Rep. 2019;57:48-51. doi: 10.1016/j.ijscr.2019.02.042. Epub 2019 Mar 6.
In modern surgical era, local haemostatic agents and blood components such as recombinant activated factor VII (rFVIIa) have expanded surgeons' armamentarium in controlling "surgical" and "nonsurgical bleeding". We report a case of intraoperative thrombosis and cardiac arrest involving use of local haemostatic agent in intraoperative cell salvage and rFVIIa administration in extended right hepatectomy.
A 46-year-old lady underwent extended right hepatectomy using cardiopulmonary bypass (CPB) and autotransfusion with ICS for metastatic gastrointestinal stromal tumour. She became extremely coagulopathic following weaning of CPB despite an array of fluid and blood products replacements. Decision to administer rFVIIa as a measure to arrest bleeding was unsuccessful. Extensive systemic thrombosis occurred which resulted in cardiac arrest and mortality.
The thromboembolic event was unclear but likely multifactorial. Two important hypotheses were the administration of rFVIIa and use of local haemostatic agent in ICS.
Reported incidence of thromboembolism with use of rFVIIa in refractory bleeding is variable. More randomised controlled trials are needed to ascertain the efficacy and safety profile of the haemostatic agent. At present, off-label use of rFVIIa should be guided by the risk:benefit profile on a case-to-case basis. The authors also feel strongly against the use of local haemostatic gel in conjunction with ICS due to potential systemic circulation of the thrombin.
在现代外科时代,局部止血剂和血液成分,如重组活化因子VII(rFVIIa),扩大了外科医生控制“手术性”和“非手术性出血”的手段。我们报告一例术中血栓形成和心脏骤停的病例,该病例涉及在术中细胞回收中使用局部止血剂以及在扩大右肝切除术中使用rFVIIa。
一名46岁女性因转移性胃肠道间质瘤接受了使用体外循环(CPB)和术中细胞回收进行自体输血的扩大右肝切除术。尽管进行了一系列液体和血液制品替代,但在CPB撤机后她出现了严重的凝血功能障碍。使用rFVIIa作为止血措施的决定未成功。发生了广泛的全身血栓形成,导致心脏骤停和死亡。
血栓栓塞事件尚不清楚,但可能是多因素的。两个重要的假说是rFVIIa的使用和术中细胞回收中局部止血剂的使用。
在难治性出血中使用rFVIIa的血栓栓塞报告发生率各不相同。需要更多的随机对照试验来确定止血剂的疗效和安全性。目前,rFVIIa的非标签使用应根据具体情况的风险效益情况来指导。作者也强烈反对将局部止血凝胶与术中细胞回收联合使用,因为凝血酶可能会进入体循环。